Dostarlimab is a Monoclonal Antibody owned by GSK, and is involved in 48 clinical trials, of which 6 were completed, 38 are ongoing, and 4 are planned.

Dostarlimab acts as an anti-PD-1 monoclonal antibody for cancer immunotherapy. Programmed death-1 (PD-1) is a negative regulator of T cell function belonging to the CD28 superfamily of T cell regulators1. PD-1 delivers negative signals through binding to its natural ligands (PD-L1 and PD-L2) which are broadly expressed and exert a wide range of immunoregulatory roles. PD-1 interaction with its ligands is important in attenuating infectious immunity and tumor immunity and facilitating chronic infection and tumor progression. Upregulation of PD-L1 on tumor cells is a widespread phenomenon and an important mechanism of avoidance of the host immune response.

The revenue for Dostarlimab is expected to reach a total of $4.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dostarlimab NPV Report.

Dostarlimab was originated by AnaptysBio and is currently owned by GSK.

Dostarlimab Overview

Dostarlimab (Jemperli) is a immunoglobulin G4 humanized monoclonal antibody, acts as anti neoplastic agent. It is formulated as solution and concentrate solution for intravenous route of administration. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.

Dostarlimab is under development for the treatment of solid tumors including gastric cancer, high-grade neuroendocrine carcinoma, advanced small cell lung cancer, adenocarcinoma of the gastroesophageal junction, head and neck cancer, biliary tract cancer, clear cell renal cell carcinoma, metastatic urothelial bladder cancer, triple negative breast cancer, refractory osteosarcoma, colorectal cancer, neuroblastoma, adrenocortical carcinoma, ewing sarcoma, rhabdomyosarcoma, metastatic pancreatic ductal adenocarcinoma, recurrent and metastatic head and neck squamous cell carcinoma, squamous non-small cell lung cancer, malignant pleural mesothelioma, cervical cancer, rectal adenocarcinoma, acral melanoma, metastatic microsatellite instability high (MSI-H) endometrial cancer, epithelial ovarian cancer, metastatic clear cell sarcoma, peritoneal cancer, gestational trophoblastic neoplasia (GTN), fallopian tube cancer, penile cancer who have progressed following one or two prior chemotherapy treatments and first line/second line non-small cell lung cancer and pan-deficient mismatch repair tumors (PdMMRT) (solid tumor). It is administered intravenously. It is an anti-PD-1 mAb. The drug candidate acts by targeting the PD-1 which has the potential to activate anti-tumor immunity. The drug candidate is developed based on somatic hypermutation (SHM) technology platform (SHM-XEL platform).

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Dostarlimab

Report Segments
  • Innovator (NME)
Drug Name
  • Dostarlimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.